首页|氧化三甲胺影响冠心病和抗血小板药物疗效的研究进展

氧化三甲胺影响冠心病和抗血小板药物疗效的研究进展

扫码查看
冠心病目前仍是全球范围(包括中国)最常见的心血管疾病和死亡原因之一.抗血小板药物是治疗冠心病的基础性药物.近年来越来越多的研究发现,肠道菌群主要代谢产物氧化三甲胺(trimethylamine N-oxide,TMAO)可通过多种机制促进动脉粥样硬化,影响冠心病患者的预后和抗血小板药物的疗效.本文就这方面的研究进行综述.
Research progress of the effect of TMAO on coronary heart disease and the efficacy of antiplatelet drugs
Coronary heart disease is still one of the most common cardiovascular disease and causes of death worldwide(including China).Anti-platelet drugs are fundamental in the treatment of coronary heart disease.In recent years,more and more studies have found that trimethylamine N-ox-ide(TMAO),a major metabolite of intestinal flora,can promote atherosclerosis through various mech-anisms,affecting the prognosis of patients with cor-onary heart disease and the efficacy of antiplatelet drugs.This article reviews the effect of TMAO on coronary heart disease and the efficacy of anti-platelet drugs.

trimethylamine N-oxidecoronary heart diseaseantiplatelet drug

彭园园、陈碧莲

展开 >

中南大学湘雅医院老年医学科,长沙 410078,湖南

氧化三甲胺 冠心病 抗血小板药物

湖南省科技厅科研项目长沙市科技局科研项目

2022JJ70156kq2202367

2024

中国临床药理学与治疗学
中国药理学会

中国临床药理学与治疗学

CSTPCD北大核心
影响因子:0.97
ISSN:1009-2501
年,卷(期):2024.29(5)
  • 26